Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications offered through RNK Health require evaluation by a licensed healthcare provider and have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Consult your healthcare provider before beginning any weight management program.
The Short Answer
RNK Health is a telehealth-based weight management and longevity platform. Patients complete an online health assessment, a licensed physician reviews the information and determines whether a prescription is appropriate, and if so, compounded medication is shipped directly to the patient's home. The primary programs involve compounded semaglutide and compounded tirzepatide — two GLP-1 receptor agonist active ingredients with an established body of clinical literature. RNK Health also offers NAD+ and Sermorelin programs for patients interested in broader longevity support.
This article explains what GLP-1 therapy is, how compounded medications differ from brand-name options, how the RNK Health process works, and what prospective patients should understand before starting. For verified pricing and a full program assessment, see our complete RNK Health review.
What Is GLP-1 Therapy?
GLP-1 stands for glucagon-like peptide-1 — a hormone naturally produced in the gut in response to food intake. It plays several roles in metabolic regulation: it stimulates the pancreas to release insulin in response to rising blood glucose, slows gastric emptying (the rate at which food leaves the stomach), and acts on areas of the brain involved in appetite signaling, producing a sense of fullness earlier and for longer than food alone typically achieves.
GLP-1 receptor agonists are medications designed to bind to the same receptors that the body's natural GLP-1 hormone activates, amplifying these effects. They do not stimulate the central nervous system the way older appetite suppressants did. They work through a hormonal pathway, which is why the clinical profile — including the side effect profile — is different from previous generations of weight management medications.
The two active pharmaceutical ingredients RNK Health's programs are built around — semaglutide and tirzepatide — are the same ingredients in the brand-name FDA-approved medications Wegovy (semaglutide, approved for chronic weight management), Ozempic (semaglutide, approved for type 2 diabetes), Zepbound (tirzepatide, approved for chronic weight management), and Mounjaro (tirzepatide, approved for type 2 diabetes). The distinction between the brand-name and compounded versions matters and is explained below.
What Does “Compounded” Mean?
Pharmaceutical compounding is the practice of a licensed pharmacist preparing a customized medication for an individual patient based on a licensed prescriber's order. Compounding has a recognized place in medicine — it allows access to medications in formulations or doses that are not commercially available, for patients with allergies to inactive ingredients in commercial products, or when commercial products are unavailable.
Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredients as the brand-name versions. What they do not have is FDA approval as finished drug products. This means they have not undergone the FDA's review process for safety, effectiveness, or manufacturing quality as a finished formulation. They are prepared by state-licensed compounding pharmacies under requirements established by state pharmacy boards and, for outsourcing facilities (503B pharmacies), by FDA oversight as well.
This distinction is not a reason to categorically avoid compounded GLP-1 medications — it is a reason to understand exactly what you are taking and to ensure the compounding pharmacy involved operates to high standards. The questions to ask a compounding pharmacy before starting are: What is your 503A or 503B designation? Are you on the FDA's registered outsourcing facilities list? Do you test finished product for potency and sterility? An operation with transparent answers to all three is meaningfully different from one that is evasive.
RNK Health's compounding pharmacy is located at 863 W 450 S, Suite 101, Springville, UT 84663. Patients can use this address to look up the pharmacy's registration status with the Utah Division of Professional Licensing and the FDA's outsourcing facility database.
How Does the RNK Health Process Work?
The intake process is fully online. Patients complete a digital health questionnaire covering their medical history, current medications, weight history, and treatment goals. A licensed physician reviews this information and determines whether a prescription for compounded semaglutide or tirzepatide is clinically appropriate. Patients who do not meet prescribing criteria are not approved — which is how a medically responsible program operates.
If a prescription is issued, RNK Health states that medication is compounded and shipped within 48 hours to the patient's address via private home delivery. All plans include the medication itself, the physician consultation and prescription management, personal coaching, required self-administration supplies (syringes and alcohol swabs for injectable formulations), and shipping — with no separately billed fees. Plans are month-to-month with no long-term contract.
Patients seeking the most detailed comparison of semaglutide and tirzepatide within the RNK Health context — including mechanism differences, trial data, and how to think about which option to discuss with a provider — should read our semaglutide vs. tirzepatide guide for RNK Health patients.
Who Qualifies?
GLP-1 receptor agonist therapy for weight management is generally evaluated for adults who meet specific BMI criteria. Standard prescribing thresholds — consistent with the FDA-approved indications for Wegovy and Zepbound — include adults with a BMI of 30 or greater (classified as obesity), or adults with a BMI of 27 or greater (classified as overweight) who have at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.
These thresholds are guidelines, not guarantees. The prescribing decision belongs entirely to the licensed physician who reviews your specific intake information. Certain medical histories are standard contraindications that a reviewing physician will evaluate: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, severe gastrointestinal conditions, current or planned pregnancy, and end-stage kidney or liver disease, among others.
Full disclosure of your medical history during the intake process is not optional — it is the mechanism by which the platform ensures the medication is appropriate for you. Incomplete disclosure creates risk. Complete disclosure allows the physician to make an informed determination, and in some cases, to recommend a different treatment approach.
What Is NAD+ and How Does It Fit?
RNK Health's NAD+ offering sits in a different category from its GLP-1 programs. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism, DNA repair, and mitochondrial function. Research on NAD+ supplementation in humans is an active and developing area; while preclinical and early-phase human studies show interesting signals around aging and metabolic function, large-scale randomized controlled trials establishing definitive clinical outcomes are still limited. Patients interested in NAD+ should review the current evidence with their healthcare provider and approach the category as an emerging area of inquiry rather than an established therapeutic intervention.
RNK Health offers NAD+ starting at $129/month in injectable, nasal spray, and liposomal liquid formats, giving patients format flexibility based on preference and comfort with self-administration.
The Bottom Line on What RNK Health Is
RNK Health is a telehealth platform that provides physician-supervised access to compounded GLP-1 medications — the same active ingredients as brand-name Wegovy and Zepbound — at a fraction of the brand-name price, with personal coaching included at no additional cost and a disclosed U.S.-based pharmacy. It is not a supplement program, not an over-the-counter solution, and not a substitute for a primary care relationship. It is a prescription telehealth service that operates within a recognized medical framework, with the attendant requirements that implies: a licensed prescriber, a licensed pharmacy, and patient responsibility for accurate medical disclosure.
For a complete program assessment including verified pricing, coaching details, and our editorial conclusions, see the RNK Health review. For safety considerations, contraindications, and what to watch for during treatment, see our RNK Health side effects and safety guide.
Frequently Asked Questions
What is RNK Health?
RNK Health is a telehealth platform that connects patients with licensed physicians who evaluate eligibility for compounded GLP-1 weight management medications — primarily compounded semaglutide and compounded tirzepatide — along with longevity therapies including NAD+. Available in all 50 states.
What does compounded mean for GLP-1 medications?
Compounded GLP-1 medications contain the same active pharmaceutical ingredient as brand-name versions but are prepared by a licensed compounding pharmacy. They are not FDA-approved as finished drug products and require a prescription from a licensed healthcare provider.
How does the RNK Health intake process work?
Patients complete a digital health assessment. A licensed physician reviews it and determines whether a prescription is appropriate. If approved, medication ships to the patient's address within approximately 48 hours of physician approval.
Who qualifies for GLP-1 therapy at RNK Health?
Standard GLP-1 prescribing criteria include adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater with at least one weight-related comorbidity. Final eligibility is determined by the reviewing licensed physician.